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Background: To investigate the relationship between age, prostate speciﬁc antigen (PSA), and prostate
volume (PV) in Indonesian men with histologically proven benign prostatic hyperplasia.
Methods: Data were generated from our BPH database from June 1994 until December 2013. Subjects
were men with a minimum age of 40 years with chief complaint of LUTS or urinary retention, diagnosed
with BPH. All patients underwent TRUS-guided prostate biopsy. Patients with PSA level >10 ng/mL were
excluded from the study to exclude the possibility of occult prostate cancer. PV was measured with TRUS.
Appropriate statistical tests were employed for data analysis.
Results: In all, 1638 patients were enrolled in our study. There was a statistically signiﬁcant difference in
PSA (P ¼ 0.03) and PV (P < 0.0001) between age groups. Overall correlation between age, PSA, and PV
were: i). Age and PV (r ¼ 0.12, P < 0.0001); ii). Age and PSA (r ¼ 0.07, P ¼ 0.008); iii). PSA and PV (r ¼ 0.26,
P < 0.0001). Subgroup analysis in terms of indwelling catheter use versus without: i). Age 66.09 ± 8 years
versus 65.38 ± 7.66 years (P ¼ 0.158); ii). PSA 4.93 ± 2.62 ng/mL versus 4.68 ± 2.82 ng/mL (P ¼ 0.038); iii).
PV 47.58 ± 21.33 mL versus 41.43 ± 20.55 mL (P < 0.0001). Correlation between age, PSA, and PV in
patients were similar in patients with and without indwelling catheter.
Conclusion: In Indonesian men with biopsy-proven BPH, both PV and PSA increased with ageing.
Prostate volume was signiﬁcantly correlated with PSA. Even though the results were weaker, these re-
sults are consistent with results in other sets of population. The results vary between different countries
and thus, ethnicities. Indonesia is a populous a sociocultural and ethnically diverse country. Therefore,
aside from PSA, age, and PV, when investigating men with BPH, ethnicity may also need to be taken into
account.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Benign prostatic hyperplasia (BPH) is a common progressive
disease in the male aging population.1 Although aging and andro-
gens are established risk factors, the cause of BPH remains uncer-
tain.2,3 Several mechanisms were hypothesized to be involved in
the progression of BPH including hormonal or vascular alterations,
inﬂammation, epithelial/stromal interactions, and luminal/epithe-
lial cell interactions.2,3
In the aging male, there is signiﬁcant tissue remodeling taking
place within the prostate. It was postulated that prostate growth isulty of Medicine University of
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s).
ciﬁc Prostate Society, Published bthe result of a disturbed balance between apoptotic and prolifera-
tive activities with a net reduction in apoptotic activity. Histologic
analysis showed a decreased apoptotic activity in glandular and
basal epithelial cells of the prostate.2e4 Thus, with increasing age
there is a tendency of increasing prostate volume (PV).
Prostate-speciﬁc antigen (PSA) is a widely used tumor marker
for prostate cancer.5,6 Although it is well known that PSA is prostate
speciﬁc, it is not a disease-speciﬁc biomarker. Several studies have
examined the relationship between PSA and PV.5,7e9 These studies
consistently showed a positive correlation between PSA level and
PV. However, these results were derived from Western and East
Asian populations, and thus may not accurately reﬂect the condi-
tions in an Indonesian population. Differences in ethnicity and
geographical factors may exert differences in BPH characteristics in
men.10,11 The exact relationship between age, serum PSA, and PV in
Indonesian men with histologically proven BPH has yet to be
established. Thus, the aim of this study was to investigate they Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1 Characteristics of 1,638 patients with histologically proven BPH.
Age (y) 65.67 ± 7.81
Age group (y)
 60 448 (27.4)
61e69 664 (40.5)
 70 526 (32.1)
PSA (ng/mL) 4.78 ± 2.74
0.02e10
PV (mL) 43.93 ± 21.08
3e174
Indwelling catheter
Yes 666 (40.7)
No 972 (59.3)
Data are presented as n (%) or mean ± SD.
PSA, prostate-speciﬁc antigen; PV, prostate volume.
Prostate Int 4 (2016) 43e4844relationship between age, PSA level, and PV in Indonesianmenwith
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2. Materials and methods
Data were generated from our BPH database from June 1994
until December 2013. These involved patients whose chief
complaint was lower urinary tract symptoms or urinary retention
who visited the Department of Urology of the “Cipto-
Mangunkusumo” Hospital. The inclusion criteria were a mini-
mum age of 40 years and a diagnosis of BPH (histopathologically
proven). Patients with indwelling catheter were those with a
history of urinary retention who failed trial without catheter
with a blocker. All patients underwent standard clinical evalua-
tion and PSA testing. Indication for prostate biopsy in our
department was a PSA value of greater than or equal to 4 ng/mL
or abnormal ﬁndings in digital rectal examination. Core biopsy
was done with an 18-gauge needle, TRUS guided, using a spring-
loaded biopsy gun (Bard Magnum). Our patients underwent a 6-
to 12-core biopsy. Those patients with biopsy results of prostate
cancer, atypical acinus, atypical small acinar proliferation, atyp-
ical adenomatous hyperplasia, and prostatic intraepithelial
neoplasia were excluded from the study. Those who consumed
5a-reductase inhibitors and those with a PSA level of greater
than 10 ng/mL (in order to avoid the possibility of occult prostate
cancer) were also excluded from the study.Age group
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Fig. 1. Median and range values, by age group. (A) ProstPatients were divided into three age groups: 60 years of age or
younger, between61and69yearsof age, and70yearsof ageandolder.
Based on the measurements obtained using TRUS, PV was calculated
using the following formula: PV¼ heightwidth length 0.52. PV
was categorized into Less than 30 mL, 31e40 mL, 41e50 mL,
51e100 mL, and greater than 100 mL.12
Descriptive statistics were used to characterize all variables. Prior
to statistical analysis, numerical data were log-transformed for
normalization. One-way analysis of variance (ANOVA) test and in-
dependent t test were used to analyze the differences in numerical
data (age, PV, and PSA) among the different age groups and catheter
use groups. Pearson's test for correlation was used to analyze the
linearcorrelationbetweenage, PSA, andPV.APvalueof less than0.05
was considered statistically signiﬁcant. Statistical analysis was per-
formedusing IBMSPSS Statistics (IBMCorp., NewYork, United States;
www.ibm.com/SPSS_Statistics) version 20.
3. Results
A total of 1,638 patients were included in our study. The char-
acteristics of these patients are presented in Table 1. The median
(range) PSA and PV in age groups  60 years, 61e69 years, and 
70 years were 4.29 (0.1e9.93) ng/mL and 30.68 (3e141.29) mL, 4.61
(0.07e10) ng/mL and 38.92 (11.4e149) mL, and 4.8 (0.02e10) ng/
mL and 40.48 (3e174) mL, respectively. There was a statistically
signiﬁcant difference in PSA (P¼ 0.03, one-way ANOVA test) and PV
(P < 0.001, one-way ANOVA test) between age groups. These results
are illustrated in Figs. 1A and 1B.
PSA was < 4 ng/mL in 715 (43.65%) patients. PV was  30 mL in
436 (26.6%) patients, 31e40 mL in 442 (27%), 41e50 mL in 296
(18.1%), 51e100 mL in 430 (26.3%), and > 100 mL in 34 (2.1%).
The correlation between age, PSA, and PV are illustrated in Fig. 2.
The results of the subgroup analysis based on indwelling catheter
use are presented in Table 2. The correlation between age, PSA, and
PV in patients with and without indwelling catheter is illustrated in
Fig. 3.
4. Discussion
BPH is age-related, and the prevalence increases with increasing
age.13,14 Among many factors that contribute to prostateAge category
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Fig. 2. Pearson's correlation coefﬁcient. (A) Between age and PV (r ¼ 0.12, P < 0.001). (B) Between age and PSA (r ¼ 0.07, P ¼ 0.008). (C) Between PSA and PV (r ¼ 0.26, P < 0.001).
PSA, prostate-speciﬁc antigen; PV, prostate volume.
Table 2 Subgroup analysis based on catheter usage.
Variable Indwelling catheter P
Yes No
Overall (y) 666 (40.7) 972 (59.3) e
 60 171 (10.4) 277 (16.9) e
61e69 267 (16.3) 397 (24.2) e
 70 228 (13.9) 298 (18.2) e
Age (y) 66.09 ± 8 65.38 ± 7.66 0.158 a)
PSA (ng/mL) 4.93 ± 2.62 4.68 ± 2.82 0.038 a)
PV (mL) 47.58 ± 21.33 41.43 ± 20.55 < 0.001 a)
a) Independent t test.
Data are presented as n (%) or mean ± SD.
PSA, prostate-speciﬁc antigen; PV, prostate volume.
Putra et al / BPH in Indonesian men 45enlargement in BPH, the two most well-known etiologic factors
were aging and androgen.3 Consistent with the theory that aging is
an etiologic factor of BPH, our results showed a trend of increasing
median PV with advancing age, with the highest PV recorded in the
 70 years group and the lowest PV in the  60 years group. This
increasing PV with aging is accompanied with an increasing trend
of PSA with age. This result is consistent with studies in Indian,
South Korean, Taiwanese, and Swedish populations (Table 3).15e19
The correlation between age and PV in our study is the weakest
(r¼ 0.12, P < 0.001). Consistent with results from other studies, PSA
was positively correlated with age in our study. However, the cor-
relation is theweakest (r¼ 0.07, P < 0.008) (Table 4) compared with
results from other studies.15e17 PSA has been suggested as an
estimator for PV.7,20,21 This is supported by the fact that prostate
epithelial cells are responsible for circulating PSA, and several
studies had documented a positive correlation between PSA and
PV.8,17,22,23 Hochberg et al8 reported a correlation coefﬁcient of
0.33e0.41 in a series of white patients. Studies in Japanese, South
Korean, and Indian patients showed a positive signiﬁcant correla-
tion coefﬁcient between PSA and PV of 0.65, 0.41, and 0.78,respectively.15,17,23 Our study showed a similar but weaker corre-
lation with a correlation coefﬁcient of 0.26 (P < 0.001). The corre-
sponding studies had a similar study design. The difference
between the degree of correlation of age with PV and age with PSA
is probably attributable to the ethnic or geographical factors that
may inﬂuence prostatic growth.10,11
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Fig. 3. Pearson's correlation coefﬁcient in patients with (AeC) and without (DeF) indwelling catheter. (A) Between age and PV (r ¼ 0.13, P ¼ 0.001). (B) Between age and PSA
(r ¼ 0.04, P ¼ 0.267). (C) Between PSA and PV (r ¼ 0.23, P < 0.001). (D) Between age and PV (r ¼ 0.11, P ¼ 0.001). (E) Between age and PSA (r ¼ 0.08, P ¼ 0.016). (F) Between PSA and
PV (r ¼ 0.28, P < 0.001). PSA, prostate-speciﬁc antigen; PV, prostate volume.
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Table 3 Correlation of age and prostate volume in different countries from
various studies.
Country Study Correlation coefﬁcient (r) P
India Baruah et al15 0.84 0.001
South Korea Lee et al17 0.32 < 0.001
Taiwan Liu et al19 0.31 < 0.001
Sweden Vesely et al16 0.25 0.001
Indonesia Our study 0.12 < 0.001
Table 4 Correlation of age and prostate-speciﬁc antigen in different countries
from various studies.
Country Study Correlation coefﬁcient (r) P
India Baruah et al15 0.77 0.001
South Korea Lee et al17 0.17 < 0.001
Sweden Vesely et al16 0.28 < 0.001
Indonesia Our study 0.07 0.008
Putra et al / BPH in Indonesian men 47We have performed a subanalysis in patients with and without
indwelling catheter, comparing age, serum PSA, and PV. Patients
with indwelling catheter tend to have a higher serum PSA
(P ¼ 0.038) and PV (P < 0.001). PSA is an organ-speciﬁc biomarker
of the prostate. Disruption of the normal anatomic prostatic tissue
results in an increase in serum PSA. This increase may result from
malignant or benign prostatic diseases or prostatic manipulation
including catheterization.24 It is also known that patients with
higher PSA and PV tend have a greater risk of urinary retention and
thus, catheterization.25,26 Although aging is related to a higher risk
for urinary retention,27 results from our study showed that there
was no difference in age in terms of indwelling catheter use. In both
groups, PV was signiﬁcantly correlated with age and PSA. Both
groups showed similar coefﬁcient correlation values.
Elevated serum PSA is observed in men with BPH, prostatitis, or
prostate cancer. In another study conducted earlier in our center,
from January 1995 to December 2014, the overall prostate cancer
detection rate was 28.7%. With speciﬁc levels of PSA 4.0e9.9 ng/mL
and 10.0e19.9 ng/mL, the prostate cancer detection rates were 9.3%
and 13.1%, respectively. Meanwhile, the overall detection rate for
PSA level 4.0e20 ng/mL was 11.3%, which was similar to that re-
ported in a study by Shahab et al.28,29 The indications for prostate
biopsy in our center were PSA > 4.0 ng/mL or abnormal digital
rectal examination (DRE) ﬁndings. We believed that the possibility
of unintentionally including patients with prostate cancer had been
minimized as much as possible as we enrolled only individuals
with a PSA of  10.0 ng/mL and histopathologically proven BPH
from either a transrectal prostate biopsy or a transurethral resec-
tion of the prostate (TURP) specimen.
The limitation of our study was that the correlations between
PSA, age, and PV found in this study were weaker than those found
in similar studies from other centers. This difference could be
attributable to methodological differences between this and other
studies; or there was a fundamental difference in the biology of
prostate (including PV and PSA) in various ethnicities.10,30,31
Indonesia, the most populous country in Southeast Asia, is a so-
cioculturally and ethnically diverse country. The heterogeneity of
our study population may account for the weak correlation coef-
ﬁcient between the investigated variables. Future studies may be
necessary to explore the correlations in speciﬁc ethnicities. A pro-
spective, multicenter, long-term longitudinal study is warranted to
address this issue.
In Indonesian men with biopsy-proven BPH, both PV and PSA
increased with aging. PV was signiﬁcantly correlated with PSA.
Even though the results were weaker, these results are consistent
with the results in other population groups. Thus, aside from PSA,age, and PV, when investigating men with BPH, ethnicity may also
need to be taken into account.Conﬂicts of interest
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